Clinical Trials - Complete NMCC List
The listing of open clinical trials below is primarily intended for medical oncologists, nurses and clinical trial coordinators. If you are a patient, we encourage you to discuss with your oncologist whether there are any clinical trials that might be of benefit to you. In the near future, we hope to have plain language descriptions of these clinical trials for use by patients.
| CURRENTLY OPEN CLINICAL TRIALS AT NMCC - Updated Dec 31, 2016 | ||
|---|---|---|
| Category | Trial # | Title |
| Breast Adjuvant | ECOG-ACRIN EA1131 | Phase III Randomized Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| Breast Adjuvant | Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03 | PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer |
| Breast Adjuvant | NSABP B-51/RTOG 1304 | Phase III Randomized Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304) |
| Breast Adjuvant | SWOG S1207 | Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| Breast Advanced | SWOG S1416 | Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Breast Advanced | ECOG E2112 | Phase III Randomized Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer |
| GU Other | NRG Oncology NRG-GU001 | Phase II Randomized Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer |
| GU Prostate Adjuvant | Pharm (Advantagene) PrTK03 | Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer |
| Head and Neck Adjuvant | ECOG-ACRIN EA3132 | Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Lung NSCLC Adjuvant | Alliance A151216 | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| Lung NSCLC Adjuvant | ECOG-ACRIN E4512 | Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| Lung NSCLC Adjuvant | Alliance A081105 | Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC); AKA ALCHEMIST |
| Molecular Genetics | INST 96144 City of Hope | Molecular Genetics Studies of Cancer Patients and Their Relatives |
| Lung NSCLC Advanced | RTOG 1306 | Phase II Randomized Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) |
| Lung NSCLC Advanced | SWOG S1403 | Phase II/III Randomized Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Naïve Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer |
| Lung Other | SWOG S1400 | Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) |
| Skin Melanoma Advanced | ECOG-ACRIN EA6134 | Phase III Randomized trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
| Skin Melanoma Advanced | ECOG-ACRIN EA6141 | Phase II/III Randomized Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma |
| Solid Tumors Other | ECOG-ACRIN EAY131 | Molecular Analysis for Therapy Choice (MATCH) |
| TOTAL TRIALS: | 19 | |